There is a popular board game based on a global disease outbreak that is generally rated 5 stars. As for the real Covid-19 pandemic, it would be hard to find a single person in the Biopharma industry who would give the supply chain performance during the pandemic that kind of high review.
mRNA technology has proven to enable rapid drug development. mRNA is an attractive modality to work with because of its relative simplicity compared to other biologics; it is wholly synthetic and does not require cellular materials.
mRNA technology offers many opportunities but the development and manufacturing of mRNA-based vaccines and therapeutics present a number of challenges. Learn more about the opportunities of the mRNA technology and how to overcome drug development and manufacturing challenges to bring your mRNA-based therapies to market in this first webinar.
This whitepaper describes the development and use of a cost model encompassing capital, labor, materials, consumables, and other costs, which are five key parameters of manufacturing for a variety of vaccine modalities: vaccines which use inactivated and attenuated viruses, protein subunit vaccines, virus-like particles (VLP) vaccines, Viral vector vaccines, and mRNA vaccines.
Get a step-by-step overview of the plasmid DNA manufacturing process and the challenges in pDNA downstream purification, for mRNA, plasmid-based DNA Vaccines, and Viral Vector applications.
Are you curious about Process Analytical Technologies (PAT), Raman spectroscopy, chemometrics and Raman applications in bioprocessing? Watch this 4 part interview series: PAT and Raman Meet the Experts Interview Series.
There is consensus among the global health community that long-term collaboration in resilient biomanufacturing capacity and supply chains…
recently commissioned Economist Intelligence Clearstate, a division of The Economist, to conduct a study on the future of…
The biopharmaceutical industry trends towards new product classes and smaller batch sizes drives even a greater need for…
Join us for this panel discussion to discover how a large global network of scientific experts, innovative technologies, and non-GMP facilities empower startups to advance scientific innovation through collaborative exploration and learning.
